Telix Pharmaceuticals Limited announced that Tiffany Olson has been appointed to the Board, as a U.S.-based independent, Non-Executive Director.
Ms. Olson brings a depth of experience in commercialisation and corporate strategy in oncology,
including in the radiopharmaceutical sector. Her most recent executive role was with Cardinal Health.
Ms. Olson will join Telix as an independent Non-Executive Director and will be a member of the Audit
and Risk Committee. Her appointment is effective 31 March 2022. Ms. Olson will stand for re-election
as a Non-Executive Director at Telix's Annual General Meeting, to be held on 18 May 2022.
Telix advises that Mr. Oliver Buck will retire from the Board at the Company's 2022 Annual General
Meeting. Having served on the Telix Board since 16 January 2017, Mr. Buck has taken the decision
to retire from the Board due to the increasing time commitment associated with his portfolio of global
Board and advisory roles.